Journal of Medical Genetics and Clinical Biology
Homepage : https://journal.antispublisher.id/index.php/JMGCB
Email : admin@antispublisher.com

e-ISSN : 3032-1085
JMGCB, Vol. 2, No. 5, May 2025
Page 169-184

Host Immune Profiling in Patients with Severe COVID-19: Biomarkers of Immune Dysregulation

Husam Fadhil Hasan[1], Mojtaba Qati Dahdoh[2], Hayder Mohsin Ali[3]
[1,2,3]Kut University College, Iraq

DOI : https://doi.org/10.61796/jmgcb.v2i5.1302

Sections Info

Article history:
Submitted: March 31, 2025
Final Revised: April 14, 2025
Accepted: April 28, 2025
Published: May 16, 2025

Keywords:
Immune profiling
Severe covid-19
Immune dysregulation
Cytokine storm
Biomarkers

ABSTRACT

Objective: *Host immune profiling in severe cases of COVID-19 is an important area of focus that seeks to explain the immune dysregulation mechanisms impacting upon health. This study examines the immune landscape of patients suffering from severe COVID-19 in detail, mapping specific biomarkers of immune dysfunction.* ***Method:*** *By harnessing advanced technologies, including flow cytometry and transcriptomic analysis, this study captures the dynamic changes within immune cell subsets and their related pathways. Central to this exploration is understanding the interplay between innate and adaptive immunity in the context of severe COVID-19 infections.* ***Results:*** *Through comprehensive analysis, the study delineates the aberrant immune responses infiltrated by SARS-CoV-2, characterized by hyper inflammation, cytokine storm phenomena, and substantial variations in immunological profiles. Detailed profiling reveals notable deviations in neutrophil counts, lymphopenia, and altered cytokine levels. These disruptions are instrumental in the cascading complexities observed during disease progression. Consequently, the research identifies potential targets for modulation and future clinical application, thus aiming to enhance recovery rates and curtail mortality linked to severe COVID-19.* ***Novelty:*** *The identification of unique biomarkers offers profound insights into pathogenic processes, presenting opportunities for targeted therapeutic interventions and improved prognostic evaluations. The research posits that a strategic approach toward host immune profiling can profoundly impact the management and understanding of COVID-19. The findings underscore the necessity for precision medicine tailored to inherent immune irregularities, advocating for the integration of identified biomarkers in clinical practices to mitigate severe disease outcomes. The study contributes to existing literature by advocating for a paradigm shift, where immune profiling informs the design of bespoke therapeutic strategies and paves the way for innovative research trajectories in combating pandemic-related challenges.*

INTRODUCTION

Glom The COVID-19 pandemic has underscored the intricate interplay between viral pathogenesis and the host immune response. While the majority of infected individuals experience mild to moderate disease, a significant subset progresses to severe or critical illness, often characterized by acute respiratory distress syndrome, multi-organ dysfunction, and heightened mortality risk. This divergence in clinical outcomes has prompted a global effort to unravel the immunological underpinnings of severe COVID-19. Central to this investigation is the need to delineate the mechanisms driving immune dysregulation, identify predictive biomarkers, and inform therapeutic strategies aimed at modulating pathological immune responses [1].

Severe COVID-19 is increasingly recognized as a syndrome of profound immune perturbation, wherein an overexuberant inflammatory response coincides paradoxically

with elements of immune suppression. Hallmark features include hypercytokinemia, described colloquially as a "cytokine storm," alongside lymphopenia, impaired antigen presentation, and functional exhaustion of T and NK cells [2]. These abnormalities, frequently accompanied by imbalances of innate and adaptive immunity, may lead to tissue injury amplified by bystander immunopathology as opposed to viral cytopathy. In addition, the diversity of host immune responses highlights the importance of immune profiling for patients stratification according to immunopathological subtypes to lead to individualized medical decision-making for treatment and management [3].

Severe COVID-19 requires a more detailed and systematic assessment of immune mediators. Many possible biomarkers have already been studied, such as increased inflammatory cytokines, perturbed interferon responses, and abnormalities in coagulation among others. These biomarkers hold value not only in diagnosis and prognosis, but in assessment of therapeutic response as well [4]. Examination of the host immune landscape may provide insights into potential new immune signatures that possibly explain the observed heterogeneity in the severity of the disease and the response to treatment. These developments hold promise for enhancing clinical decision-making, expediting the process of designing precise therapies, and deepening the understanding of the pathophysiology along with the intricate frameworks of immunology in infectious diseases [5].

Background on COVID-19

The coronavirus disease-2019 had thrown a huge stressor on grasping knowledge of SARS-CoV-2, the virulent entity responsible for the unprecedented global health crisis. Eventually, the virus surfaced from Wuhan, China, at the end of 2019, and by the end of March, it took form as a pandemic and reached the portals of millions all over the world, reconciling lives and economies into chaos as never before. SARS-CoV-2 is a positive-sense single-stranded RNA virus in the family Coronaviridae and in the β-coronavirus genus, which is compositionally very close to the coronaviruses causing severe acute respiratory syndrome and Middle East respiratory syndrome. The virus hits the target respiratory system, leading to manifestations in a wide spectrum from mild flu-like ailments to severe pneumonia and acute respiratory distress syndrome of clinical severity [6].

In order to comprehend the effects of COVID-19, it is necessary to explore its modes of transmission and its pathophysiological effects in humans. SARS-CoV-2 is mainly transmitted by respiratory droplets and secondarily by aerosol, and close human proximity seems to play a prominent role in its dynamical transmission. The virus uses its spike glycoprotein to attach to the angiotensin-converting enzyme 2 (ACE2) receptors of host cells that allows the virus to enter host cells and replicate [7]. Differences in clinical outcomes among patients with COVID-19 has emphasized the role of both host characteristics (eg, age and comorbidities) and viral characteristics (eg, mutations that increase transmissibility or virulence). The complexity of the host immune response, with dysregulation and hyperinflammation often observed in severe cases, underscores the

necessity for comprehensive immune profiling to identify biomarkers of immune dysfunction [8].

Furthermore, active research has shown that COVID-19 caused several immune responses, some of which resulted in a cytokine storm, an exaggerated immune response that is involved in severe disease and injury to organs. Knowing the molecular and immune mechanisms responsible for the pathogenicity of SARS-CoV-2 helps not only with creating treatment options but also with devising public health policies aimed at reducing the impact of the pandemic. This context helps explain the importance of studying host immune profiling, which is vital for biomarker discovery linked to disease advancement and clinical outcome prognosis in patients with severe COVID-19 [9].

RESEARCH METHOD

This research describes and analyzes immune dysregulation in COVID-19 patients, and employs profiling techniques on the host's immune system. The information included in this paper was collected from peer-reviewed journals and attempts to focus solely on the core methods such as flow cytometry, mass cytometry, and single cell RNA sequencing. These techniques were selected because they can accurately characterize immune cell subset, activation, and cytokine profile as well as provide a high throughput resolution. These findings were integrated with the hope of understanding the immunopathological mechanisms that operate within severe COVID-19 cases and enabling the formulation of precision medicine approaches to enhance clinical results.

RESULTS AND DISCUSSION

Immune Response to Viral Infections

The immune response to a viral infection is highly dynamic and sophisticated and helps preserve the host's defense against infectious agents. Such a combination of responses begins when particles of the virus invade the host leading to the activation of both innate and adaptive arms of immune system. The innate immune system is the primary responder; it deploys physical structures like skin and mucuous membranes as well as immune components such as macrophages, dendritic cells and natural killer cells. They are able to synergistically respond and recognize pathogenic signatures through their pattern recognition receptors by recognizing multiple recurring motifs associated with the virus. The activation of these receptors leads to the release of signaling molecules, notably interferons and cytokines, which facilitate an antiviral state and recruit additional immune cells to the site of infection, thereby containing the viral spread [10].

As the innate response identifies and attempts to restrain viral incursions, the adaptive immune system is simultaneously activated to mount a highly specific response. This system, characterized by its ability to confer immunological memory, entails the proliferation of antigen-specific lymphocytes, including B cells and T cells. B cells, upon encountering antigens, differentiate into plasma cells that produce antibodies, which neutralize viruses by binding to them and preventing their entry into host cells.

Conversely, T cells, which encompass cytotoxic T lymphocytes and helper T cells, perform essential roles in identifying and destroying infected host cells and in orchestrating the broader immune response. Cytotoxic T cells, through their receptor interactions, eliminate virus-infected cells, while helper T cells bolster the activity and efficiency of other immune cells through cytokine secretion [11].

Despite the precision of the immune response, viral pathogens have evolved various mechanisms to evade and manipulate host defenses. These include alterations in viral proteins to avoid immune detection, suppression of antigen presentation, and interference with immune cell signaling. Understanding these interactions and countermeasures is critical for developing effective therapeutic interventions against viral agents. Consequently, the investigation into host immune profiling offers insights into the biomarkers of immune dysregulation, paving the way for the enhancement of diagnostic and therapeutic strategies tailored for severe cases and other viral infections [12].

Pathophysiology of Severe COVID-19

Severe COVID-19 manifests through a complex array of pathological mechanisms which often culminate in severe respiratory conditions and multi-organ failure. This evolution from mild to severe illness is largely attributed to an exaggerated host immune response, characterized by dysregulated inflammatory processes. Primarily, the virus enters host cells via the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in epithelial tissues, particularly those of the respiratory tract. Once inside, viral replication triggers a cascade of immune responses, initially localized but potentially progressing to systemic involvement [3].

The initial phase of COVID-19 is usually marked by an adequate antiviral immune response; however, when this protective mechanism spirals out of control, it can lead to a "cytokine storm." This hyperinflammatory state is a hallmark of severe COVID-19 and is associated with the excessive secretion of pro-inflammatory cytokines. The resultant cytokine release syndrome may lead to increased vascular permeability, multi-lobular pneumonia, and acute respiratory distress syndrome. The affected endothelium fails to maintain vascular stability, further contributing to coagulopathy, which manifests as thrombotic complications in many patients. This pathogenic interplay highlights the pivotal role of the host's immune dysregulation in the severity of disease progression [13].

Furthermore, alterations in immune cell phenotypes have been observed in severe COVID-19 cases. Lymphopenia, particularly a reduction in CD4+ and CD8+ T cells, critically impairs the adaptive immune response. Concurrently, there is often an increase in exhausted or dysfunctional T cells, which diminishes the body’s ability to clear the virus efficiently. In addition, hyperactivation of myeloid cells, such as monocytes and macrophages, perpetuates inflammation, exacerbating tissue damage. Understanding these sophisticated immune pathophysiological mechanisms is vital for developing targeted therapies aimed at mitigating immune dysregulation, thereby reducing morbidity and mortality associated with this virulent infection [14].

Host Immune Profiling Techniques

Host immune profiling techniques have advanced our understanding of the severe perturbations of immune system functions in COVID-19. These approaches shed light on the regulated host responses by describing immune cell subsets, their functions, and their pathological changes. Profiling methods enable the analysis of cellular and molecular constituents of hyperinflammation, lymphopenia, and other forms of immune dysregulation in critically ill patients [15]. Each technique contributes to a collective understanding of host immunity. As such, each is essential for biomarker identification and therapeutic stratification. Using flow cytometry, one can conduct detailed immune profiling because it enables fast quantitative and qualitative assessments of cellular populations based on surface and intracellular markers. With fluorescently labeled antibodies, researchers and clinicians can phenotype immune cells, quantify cytokine production, and determine activation levels [16]. This technique has uniquely positioned itself to determine T-cell exhaustion, the expansion of myeloid-derived suppressor cells, and shifts in B-cell populations—all components part of the severe COVID-19 phenotype. Despite being the most widely available and simplest method for conducting immune profiling, flow cytometry is the most limited in its ability to measure numerous parameters at once which hinders its applicability in complex diseases like COVID-19.

Mass cytometry, or cytometry by time-of-flight, helps to bridge this gap by providing simultaneous analysis of more than 40 parameters at a single cell level using metal isotope-tagged antibodies [17]. This approach makes immune profiling possible, aiding in the detection of rare or faint subpopulations of immune cells and their phenotypic diversity. In the case of severe COVID-19, mass cytometry has been critical to the understanding of immune dysregulation such as hyperactive monocytes, unconventional T cells, and aberrant NK cell functions. Its logistical challenges include advanced technical complexity, cost, and relatively slow data acquisition in comparison with flow cytometry [18]. Alongside cytometry-based approaches, single-cell RNA sequencing provides transcriptomic data that reveal distinct immune cell features, functional states, lineage relationships, and intercellular signaling pathways, revealing activities and relationships that were previously obscured. This technique has documented transcriptional changes associated with greater disease severity, such as interferon exhaustion, polarization of pro-inflammatory macrophages, and decreased responses to antiviral drugs [19]. It is a valuable tool for discovery, distinguishing previously undetected immune cell subsets and pathways, some of which could be harnessed as therapeutic targets or prognostic indicators. Yet this technique's revolutionary potential is hampered by the complex computing needs it entails, restricting easy integration into clinical workflows.

In conclusion, different immune profiling techniques have their unique advantages, which when combined, provide a comprehensive understanding of immune system dysregulation in severe forms of COVID-19. The persistent use of these techniques continues to reveal the complexities of host-pathogen relationships which propel

advancements in personalized medicine and immunotherapy tailored to individual needs [20].

Flow Cytometry

In the context of severe COVID-19 infections, flow cytometry allows for laser analysis of T cells to immune profile cleave interactions. This technique provides observations on how the immune system interacts during infection by measuring careful "cross measurements" – complex blending of different measurements on the immune system. Invasion of severe COVID-19 causes distinct immune dysregulation, thus, it is important to make flow cytometry pass in identifying biomarkers of anomalous immune physiology. It accurately evaluates different populations of the immune cells and identifies anomalies associated with the severity of the disease. Through the use of fluorescently labeled antibodies, T cells, B cells, and monocytes can be quantified together at their respective activation levels. In severe cases, distinct immune features such as lymphopenia and dysfunctional T cells [21] are found. Flow cytometry is used to describe these responses to illuminate mechanisms of COVID-19 pathophysiology. Improvements in multicolor flow cytometry allow the addition of more than one measurable marker and permit simultaneous measurements to be made, a consideration that is often crucial for studying the changes and dynamics of the immune system, for observing the immune reaction to a stimulus these include the cell numbers, their true activity, and cytokines secreted; these parameters allow for sub-classifying a patient determine treatment tailored to their immune system and what they need. As research improves, flow cytometry remains pivotal in merging clinical practice with immunology [20].

Mass Cytometry

Mass cytometry integrates flow cytometry with mass spectrometry to provide detailed immune profiling, which aids in analyzing immune landscapes in severe COVID-19 cases. This technique provides insights into immune cell phenotypes and functions by measuring multiple parameters at a single-cell level. Spectral overlap is minimized by metal isotopes used for antibody labeling, allowing detection of over 40 markers per cell. In the context of severe dysregulated COVID-19, mass cytometry is important for population—delineating immune responsive T cell subtypes, B cells, and innate immune cells—which is crucial to characterizing immune signatures essential to outcome [18]. It aids in identifying immune responses and by mapping the distribution of immune cells along with their states; it helps establish disease severity biomarkers as well as define the imbalance in the underlying pathophysiological processes to facilitate the design of targeted therapeutic approaches. The multi-parameter data can be integrated with clinical data to study host-pathogen relationships to reveal undiscovered patterns and determine illness advancement and response to treatment. Mass cytometry addos not only enables the study of the immune control failure in COVID-19 but also aids in the advancement of precision medicine, broadening optimal strategies for enhancing clinical interventions and outcomes in patients during and after pandemics [22].

Single-Cell RNA Sequencing

The application of single-cell RNA sequencing (scRNA-seq) sheds light on the immune landscape of severe COVID-19, underscoring the degree of cellular heterogeneity and transcriptional dynamism. It shows how the immune response to the virus is part of the viral pathogenesis. Severe cases often have poor outcomes due to an over-dysregulated immune response. scRNA-seq allows characterizing immune signatures associated with these outcomes. Immunologists discover predictive biomarkers from analyzing RNA of individual cells, which can guide clinical decision-making, enhance prognostic accuracy, and optimize therapeutic strategies [23]. scRNA-seq traces immune responses documenting the progression of various cell states and defining the major T cell and monocyte subsets that participate in cytokine storms. Unlike bulk RNA sequencing, which averages the signals and thus erases the cellular heterogeneity, scRNA-seq reveals previously unrecognized subpopulations that may be of therapeutic value. In severe COVID-19, single-cell transcriptomics dstages combines spatial and temporal dimensions, highlighting the movements and interactions within and between tissues. Efforts to understand the mechanisms driving immune dysregulation help in designing interventions to recalibrate an overactive immune system and refine treatment approaches tailored to the complexities of severe COVID-19 [24].

Dysregulation of Immune Responses and Biomarkers

In the context of COVID-19, the immune system's dysregulation, particularly in the severe cases, demands biomarkers that assist in understanding response to the disease and formulate strategies on how to manage it. The most important of these are the markers of immune activation such as the cytokine profiles. Patients suffering from severe illness frequently undergo "cytokine storms," where pro-inflammatory cytokines like interleukin-6 and tumor necrosis factor alpha are released in great excess, leading to further injurious processes like organ failure. These processes all help in predicting the disease outcome. Identifying these profiles aids clinicians in risk evaluation and management of targeted anti-inflammatory intervention aimed at increasing the overall outcome of the treatment [12]. The presence of markers of T cell exhaustion indicate greater problems in immunity due to the accumulation of viral particles which increases PD-1 expression on T cells and is associated with waning functions. The evaluation of these markers reflects compromised immune system and targets for therapy. B cell dysfunction is also observable; in severe COVID-19, patients exhibit abnormal frequencies of plasmablast and memory B cells which inhibits the ability to mount an appropriate antibody response. The expression of CD27 which is important for the signaling of B cells issuing commands vital reactive plays a crucial role. Reduced CD27 expression is evidence of profound B cell dysfunctions that is required for adaptive immune response which enhances the understanding of the pathology of COVID-19 and precision medicine which aims to tailor interventions based on individual's immunological profile to improve the overall outcomes [25].

Cytokine Profiles

Understanding immune dysregulation in severe cases of COVID-19 is characterized by a hyperactive immune system response or "cytokine storm," which causes extensive tissue damage and other severe symptoms. Severe cases of COVID-19 are marked by hyper inflammation, also known as a "cytokine storm," in which tissue damage occurs. An analysis of immune response, especially with regard to key cytokines, is crucial in determining interleukin-6, interleukin-1β and tumor necrosis factor-alpha. All these pro inflammatory cytokines are critical in assessing immune dysregulation and disease severity. These include elevated morbidity and mortality and ascertaining could be significant as prognostic markers. This profile also reveals an intricate network of signaling that is responsible for initiating the interleukin. Interleukin-6 is crucial in providing a link between inflammation and damage. Monoclonal antibodies against interleukins can help alleviate the effects of cytokine storms. Furthermore, measuring anti inflammatory cytokines interleukin-10 is relevant alongside incomplete pleiotropy overlaps using linear regression. Immune equilibrium could only be achieved by added balance with pro-and anti-inflammatory cytokines. The investigation of cytokine profiles not only reveals treatment target possibilities, but also supports tailored approaches that improve therapeutic interventions for patients with severe COVID-19 [26].

T Cell Exhaustion Markers

In patients suffering from severe COVID-19 infection, immune system imbalance due to T cell exhaustion is critical because responses from T cells integral to the immune responses become functionally exhausted due to chronic antigenic stimulation. This dysfunction is demonstrated by upregulation of expression of inhibitory immune receptors-modules which curtail immune system activation to prevent an autoimmune pathology but such mechanism also diminishes effector functions and compromises viral eradication in persistent infections. This describes the phenomenon where the immune system is responding too much and in the wrong way which results in the immune system cleaning the body to the point of causing storms of cytokines and worsens the clinical picture. It is necessary to stress the importance of why these specific profiles need to be understood to calibrate precise targeted immune interventions. With more defined pathways, exhausted T cells can be rejuvenated without triggering adverse autoimmune damage. Defining these markers will lead to tailored modulators of immune response that precisely adjust clinical prediction models and treatment strategies. They are critical for discerning immune path dysregulation in severe COVID-19 bound patients serving as indicators of the immune system's condition and possible strategies capable of re-establishing immune function and enabling recovery [27].

Indicators of B Cell Dysfunction

B cells mediate the humoral immune response through the production of antibodies, defense against pathogens, and the formation of immunological memories. The most profound immune system impairments were marked by severe COVID-19 associated B cell dysfunction. It is important to examine the B cell abnormalities in COVID-19 patients for understanding underlying processes of the disease and for the

design of specific interventions [28]. Crucial indicators of dysfunction include immunoglobulin production where marked alterations are observed; patients have elevated IgG and IgA but poor virus neutralization which suggests B cells are unable to neutralizing antibodies, which significantly contributes to the viral persistence and severity of the disease. Furthermore, changes in the distribution of B cell subsets such as increased CD19+CD21low B cells are associated with autoimmune diseases as well as irrational omnipotent inflammation in severe cases. These changes include hyperactivation and exhaustion of B cells which has been shown by increased expression of CD95 leading to excess apoptosis and senescence which diminish immune responsiveness [21]. Atypical memory B cells, which lack defined markers, suggest that memory formation is impaired post infection which compromises long-term immunity and the effectiveness of vaccines.

To summarize, severe cases of COVID-19 are linked to dysfunctional and unbalanced antibody responses, altered distributions of B cells, and exhaustion, highlighting areas where research is needed to focus on restoring adequate antiviral B cell immunity and activity [29].

Clinical Implications of Immune profiling

The use of immune profiling in the context of severe COVID-19 bears clinical repercussions that have the potential to change patient management and treatment paradigms. Evaluation of certain immune disorder markers allows health practitioners to understand the course of the disease and customize their treatment strategies. How immune features of the individual influence the severity of the illness plays an important role for efficient risk assessment. Predictive biomarkers of disease severity significantly enhance strategic resource distribution and health outcomes [30]. Tailored therapeutic approaches determine the immunological condition of the patient. Classifying patients through immune profiling enables clinicians to provide the most appropriate and effective interventions. Those patients with hyperinflammation will likely need some form of active immunomodulation, while others might just need passive supportive care. Such strategies ought to minimize side effects and maximize therapeutic effectiveness, which refines and optimizes treatment pathways for severe COVID 19. Incorporation of this knowledge can help develop better prognostic determinants and therapeutic strategies, which can change the course of the COVID-19 pandemic or any future pandemics [31].

Forecasting the Impact of Illness

The right treatment strategy for a patient with severe COVID-19 is reliant on accurately predicting disease severity. The immune response of a host is a part of the pathogenesis of COVID-19; immune profiling reveals prognostic biomarkers. Some studies have looked into immune signatures of severe disease focused on cytokines and other immune parameters to understand immune dysregulation. Marked severe disease and poor prognosis are correlated with a cytokine storm, increased levels, and moreover the presence of pro-inflammatory cytokines such as IL-6 and TNF-alpha – reinforcing the necessity to track these markers [9]. Immune exhaustion is indicated by attending

lymphopenia, especially with regard to T-cells. Flow cytometry and other multi-omics technologies are able to construct an immune landscape for predictive stratification and severing delineation. Meng et al highlighted the need for static and dynamic, cross-sectional and longitudinal data integration to cope with the fast-paced shifts in the pandemic. These biomarker validations are critical to the evolution of personalized medicine and enabling prudent spending of medical resources while fostering better outcomes. Immune profiling data can improve models for disease management and add accuracy to model-based predictions [32].

Patient Studies and Research

As one investigates the immune interactions in the context of severe COVID cases, there is profound neglect on the complex interplay of the virus with the immune system. The examination of ICU patients demonstrates the most severe extremes of the disease itself, as well as the diverse anatomy of immune responses that extremes of hyperactive and suppressed functions simultaneously. Some patients demonstrating elevated levels of cytokines also develop ARDS and multi-organ failure as a result of severe covid induced Cytokine Storms. Often profiles demonstrate lymphopenia alongside exhaustion of T cells, both greatly constrain the anti-viral response. Immune modulators such as corticosteroids, monoclonal antibodies, and cytokine inhibitors were the initial focus of different developed therapies through the trials, which aim to determine what these severely ill patients lose and gain as interventions are tried. Indifferent to these questions, the trials adjust their attention to the most effective dose and time to give the drug to best eliminate the harms. Dexamethasone has moderated the over-offensive thrust of protective responses towards an excess of inflammation and has been protective of the self non-injurious immune modulation in active immune inhibition, performing best in this role for those defenses. In any case, these studies deepen and broaden the humble understanding of immune dysregulation in and add relevant marked phrase case covid 19, interpreting it through the lens of guided personalized medicine [33].

Case Study 1: Immune Response in ICU Patients

In severe COVID-19 cases, especially in ICUs, the immune response significantly influences outcomes. Many patients experience a "cytokine storm," leading to tissue damage and organ failure. This study examines immune landscapes in ICU patients and biomarkers of immune dysregulation. Markers like IL-6, CRP, and D-dimer correlate with disease severity and mortality. Elevated IL-6 indicates immune activation, aiding assessment of disease progression. Lymphopenia, seen in reduced CD4+ and CD8+ T cells, signifies impaired immunity, crucial for preventing severe issues. Immune dynamics research offers insights into COVID-19 and highlights intervention areas. Investigations into anti-cytokine therapies targeting IL-6 seek to reduce detrimental immune responses. By focusing on personalized medicine, immune profiling aims to create tailored treatments that enhance survival and reduce ICU duration for severe COVID-19 patients [34].

Evaluating immune modulators in the treatment of severe COVID-19 inflammation focuses on enhancing outcomes, and clinical trials are important for these purposes.

Immune balance can be restored with these modulators which include cytokine inhibitors, monoclonal antibodies, and other small molecules. Different study designs evaluate safety and efficacy of these immune balance restorers, with some cytokine inhibitors having the capability to reduce the need for mechanical ventilation, though mortality results are inconsistent. An IL-1 pathway drug demonstrates promise, and highlights the importance of personalized medicine via C-reactive protein and other biomarkers. Monoclonal antibodies directed at the SARS-CoV-2 spike protein are designed to reduce viral loads, and their effectiveness is challenged by new variants. In COVID-19 severe cases, small molecules that block inflammatory pathways reveal additional aspects of immune dysfunction [26].

Limitations of Current Research

Methodological techniques pose constraints on understanding the immune system with respect to patients suffering from severe COVID-19. A significant drawback is the heterogeneous nature of the patient cohorts, which results in variance and makes universal biomarker identification easier. This diversity is a result of intrapopulation genetic differences, comorbidities, and inter-infecting viral strains, which makes immune markers hard to consistently define. In addition, numerous studies primarily center on certain time points, which contributes to a lack of longitudinal analysis necessary to understand immune dysregulation over time [35]. Technological factors also contribute; while high-throughput sequencing and flow cytometry enable finer resolution of the immune profile, they are limited by sample quality and other methodological standards, which ultimately impacts reproducibility. Besides, the large-size emerging omics datasets are bound to be relevant, but biomarker selection usually entails sophisticated or unavailable bioinformatics. Even though animal models and in vitro investigations provide answers, they usually oversimplify the intricate human responses [36]. These challenges require a multitude of initiatives, such as standardizing and refining methodologies, in addition to reducing variability, improving the resolution of the conclusions drawn about immune dysregulation in severe COVID-19.

Viral strains and genetic diversity in universal biomarkers can be better understood through collaborative research initiatives, while improving bioinformatics infrastructure is critical for managing responsive data and obtaining fundamental insights into the dynamics of immune response [37].

Comparative Study with Other Viral Infections

Severe COVID-19 highlights the immune dysregulation's contribution to the disease severity by comparing the immune dynamics to other viral infections like influenza, SARS, and HIV. A number of viral infections ever provoke the immune system; nevertheless, COVID-19 portrays complex hyperinflammatory responses along with immune exhaustion [38]. This form of dysregulation mirrors characteristics of severe influenza and diverges greatly from it at the same time, thus aiding in enriching the understanding of host immune responses. Both severe influenza and COVID-19 exhibit heightened innate immunity along with increased pro-inflammatory cytokines which could lead to cytokine storms and tissue damage. Nevertheless, SARS-CoV-2

causes much more severe lymphopenia and delayed type I interferon responses, leading to longer incubation periods and persistent viremia [39]. Studies on SARS-CoV and MERS-CoV show shared patterns of lymphocyte depletion but divergent cytokine responses and disease trajectories. Most notably, SARS-CoV-2 demonstrates distinct elevations in neutrophil-to-lymphocyte ratios and aberrant T cell subsets which distinguish it from other coronaviruses. Chronic infection such as in HIV helps illustrate continual patterns of immune dysregulation. Both conditions, severe COVID-19 and HIV, display T cell exhaustion and expression of various inhibitory molecules but diverge on immune impacts where COVID-19 is marked with intermittent hyper-activation and suppression [40]. This demonstrates the vast immune responses adaptations to specific virus and underlines the danger of lacking defined therapeutic strategies.

Examining the immune abnormalities of COVID-19 through the lens of viral immunopathogenesis will help us define important biomarkers and mechanisms that could enhance prognostic and therapeutic approaches [41].

Role of Genetics in Immune Response

The human immune response to severe COVID-19 is influenced by genetic factors affecting innate and adaptive immunity. Genetic variations in immune-related genes determine the strength of immune activation, impacting susceptibility, disease severity, and viral clearance. Polymorphisms affecting antigen recognition, cytokine signaling, and immune cell function are key to understanding individual outcomes [42]. Variations in the human leukocyte antigen complex can enhance viral epitope recognition or enable immune evasion, thus affecting disease progression. Genetic variations that control type I and III interferon signaling are crucial in initial antiviral responses. They may hinder interferon deployment, leading to unchecked viral replication and hyperinflammatory conditions in severe cases. Genetic predispositions are linked to cytokine release syndrome in critical COVID-19 cases, with polymorphisms in genes like interleukin-6 and tumor necrosis factor-α being associated with excessive immune responses. Dysregulation of the complement system due to genetic variants correlates with increased inflammation and tissue injury. Protective polymorphisms may reduce disease severity [43]. These insights underline the role of host genetics in the immune response to severe COVID-19, explaining clinical variations. Ongoing genomic research aims to enhance understanding, paving the way for precision medicine [44].

CONCLUSION

Fundamental Finding : This study deepens our understanding of host immune profiling in patients with severe COVID-19 by elucidating the role of key biomarkers in immune dysregulation. The findings demonstrate that severe cases are marked by distinctive immunological disturbances, such as elevated levels of interleukin-6, C-reactive protein, and D-dimer, alongside lymphocyte exhaustion and impaired innate immune cell functions. These parameters not only characterize the pathological immune response but also serve as valuable prognostic markers that can stratify disease severity and guide targeted therapeutic strategies. **Implication :** The identification of specific

immune profiles associated with severe COVID-19 carries significant clinical implications. It enables a more precise approach to treatment by tailoring interventions based on a patient's immunological status. This stratification supports the application of personalized medicine and informs decisions surrounding anti-inflammatory and immunomodulatory therapies. Furthermore, the elucidation of immune biomarkers provides a foundation for developing novel therapeutic strategies that aim to correct or modulate immune dysfunction in critically ill patients. **Limitation :** Despite its valuable insights, this study has several limitations. The analysis primarily focuses on acute immune responses during severe infection, without extensive exploration of post-infection immune trajectories. Moreover, the heterogeneity in patient demographics and comorbidities may introduce variability that limits the generalizability of the findings. The reliance on cross-sectional immune profiling, rather than longitudinal tracking, also restricts the ability to fully understand the dynamic evolution of immune responses over time. **Future Research :** Future investigations should prioritize longitudinal studies that assess the persistence and evolution of immune dysregulation post-COVID-19, especially in relation to long-term outcomes and sequelae. Additionally, research exploring the interplay between host genetic factors and immune responses could unveil crucial insights into individual susceptibility and resilience. Expanding the scope to include diverse populations and integrating multi-omics approaches may further refine our comprehension of immune-mediated mechanisms and support the development of more effective, individualized treatment pathways.

REFERENCES

[1] Y. D. Gao *et al.*, "Risk factors for severe and critically ill COVID-19 patients: a review," *Allergy*, vol. 76, no. 2, pp. 428–455, 2021, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1111/all.14657

[2] F. J. Ryan *et al.*, "Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection," *BMC Med.*, vol. 20, pp. 1–23, 2022, [Online]. Available: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02286-9

[3] P. Brodin, "Immune determinants of COVID-19 disease presentation and severity," *Nat. Med.*, 2021, [Online]. Available: https://www.nature.com/articles/s41591-020-01202-8

[4] A. Bodaghi, N. Fattahi, and A. Ramazani, "Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases," *Heliyon*, 2023, [Online]. Available: https://www.cell.com/heliyon/fulltext/S2405-8440(23)00105-3

[5] A. Baghela *et al.*, "Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures," *EBioMedicine*, vol. 75, 2022, [Online]. Available: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00554-1/fulltext

[6] W. G. Land, "Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome—with a preliminary reference to SARS-CoV-2 pneumonia," *Genes Immun.*, 2021, [Online]. Available: https://www.nature.com/articles/s41435-021-00137-6

[7] U. Ranga, "SARS-CoV-2 aerosol and droplets: an overview," *VirusDisease*, 2021, [Online]. Available: https://link.springer.com/article/10.1007/s13337-021-00662-3

[8] G. Costagliola, E. Spada, and R. Consolini, "Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19," *Immunity, Inflamm. Dis.*, vol. 9, no. 2, pp. 331–339, 2021, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/iid3.403

[9] B. Hu, S. Huang, and L. Yin, "The cytokine storm and COVID-19," *J. Med. Virol.*, 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267170/

[10] M. S. Diamond and T. D. Kanneganti, "Innate immunity: the first line of defense against SARS-CoV-2," *Nat. Immunol.*, 2022, [Online]. Available: https://www.nature.com/articles/s41590-021-

01091-0
[11] A. Kałużna, P. Olczyk, and K. Komosińska-Vassev, "The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis," *J. Clin. Med.*, 2022, [Online]. Available: https://www.mdpi.com/2077-0383/11/12/3404
[12] M. S. Abers *et al.*, "An immune-based biomarker signature is associated with mortality in COVID-19 patients," *JCI Insight*, vol. 6, no. 1, p. e144455, 2021, [Online]. Available: https://insight.jci.org/articles/view/144455
[13] B. M. Liu, T. B. Martins, L. K. Peterson, and H. R. Hill, "Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review," *Cytokine*, 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473022/
[14] M. Kubánková *et al.*, "Physical phenotype of blood cells is altered in COVID-19," *Biophys. J.*, vol. 120, no. 14, pp. 2838–2847, 2021, [Online]. Available: https://www.cell.com/biophysj/fulltext/S0006-3495(21)00441-6
[15] S. Aggarwal, A. Acharjee, A. Mukherjee, M. S. Baker, and S. Srivastava, "Role of multiomics data to understand host–pathogen interactions in COVID-19 pathogenesis," *J. Proteome Res.*, vol. 20, no. 2, pp. 1107–1132, 2021, [Online]. Available: https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00917
[16] B. Shibru *et al.*, "Detection of immune checkpoint receptors–a current challenge in clinical flow cytometry," *Front. Immunol.*, vol. 12, p. 694055, 2021, [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2021.694055/full
[17] L. P. Arnett *et al.*, "Reagents for mass cytometry," *Chem. Rev.*, vol. 123, no. 3, pp. 1166–1205, 2023, [Online]. Available: https://pubs.acs.org/doi/10.1021/acs.chemrev.2c00401
[18] C. E. Burnett *et al.*, "Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients," *Immunity*, vol. 55, no. 7, pp. 1284–1298, 2022, [Online]. Available: https://www.cell.com/immunity/fulltext/S1074-7613(22)00317-5
[19] K. A. Jagadeesh *et al.*, "Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics," *Nat. Genet.*, vol. 54, no. 10, pp. 1479–1492, 2022, [Online]. Available: https://www.nature.com/articles/s41588-022-01179-8
[20] S. Varchetta *et al.*, "Unique immunological profile in patients with COVID-19," *Cell. Mol. Immunol.*, vol. 18, no. 3, pp. 604–612, 2021, [Online]. Available: https://www.nature.com/articles/s41423-020-00595-7
[21] M. Jamal *et al.*, "Immune dysregulation and system pathology in COVID-19," *Virulence*, vol. 12, no. 1, pp. 918–936, 2021, [Online]. Available: https://www.tandfonline.com/doi/full/10.1080/21505594.2021.1916411
[22] M. C. Jaimes, M. Leipold, G. Kraker, E. A. Amir, H. Maecker, and J. Lannigan, "Full spectrum flow cytometry and mass cytometry: A 32-marker panel comparison," *Cytom. Part A*, vol. 101, no. 11, pp. 942–959, 2022, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/cyto.a.24562
[23] L. Y. R. Wong and S. Perlman, "Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses—are we our own worst enemy?," *Nat. Rev. Immunol.*, 2022, [Online]. Available: https://www.nature.com/articles/s41577-021-00656-2
[24] L. Huang *et al.*, "Dynamic blood single-cell immune responses in patients with COVID-19," *Signal Transduct. Target. Ther.*, vol. 6, no. 1, p. 110, 2021, [Online]. Available: https://www.nature.com/articles/s41392-021-00531-3
[25] A. Kusnadi *et al.*, "Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2–reactive CD8+ T cells," *Sci. Immunol.*, vol. 6, no. 55, p. eabe4782, 2021, [Online]. Available: https://www.science.org/doi/10.1126/sciimmunol.abe4782
[26] A. A. Rabaan *et al.*, "Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm," *Vaccines*, vol. 9, no. 5, p. 436, 2021, [Online]. Available: https://www.mdpi.com/2076-393X/9/5/436
[27] M. S. Rha and E. C. Shin, "Activation or exhaustion of CD8+ T cells in patients with COVID-19," *Cell. Mol. Immunol.*, 2021, [Online]. Available: https://www.nature.com/articles/s41423-020-00562-2
[28] H. A. Shuwa *et al.*, "Alterations in T and B cell function persist in convalescent COVID-19 patients," *Med*, vol. 2, no. 6, pp. 720–735, 2021, [Online]. Available: https://www.cell.com/med/fulltext/S2666-6340(21)00147-9
[29] J. L. Yates *et al.*, "Serological analysis reveals an imbalanced IgG subclass composition associated

with COVID-19 disease severity," *Cell Reports Med.*, vol. 2, no. 7, 2021, [Online]. Available: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00212-1

[30] T. W. Leulseged *et al.*, "Laboratory biomarkers of COVID-19 disease severity and outcome: Findings from a developing country," *PLoS One*, vol. 16, no. 3, p. e0246087, 2021, [Online]. Available: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246087

[31] S. P. Kubli, T. Berger, D. V Araujo, L. L. Siu, and T. W. Mak, "Beyond immune checkpoint blockade: emerging immunological strategies," *Nat. Rev. Drug Discov.*, vol. 20, no. 12, pp. 899–919, 2021, [Online]. Available: https://www.nature.com/articles/s41573-021-00226-0

[32] W. Jiang *et al.*, "Exhausted CD8+ T cells in the tumor immune microenvironment: new pathways to therapy," *Front. Immunol.*, vol. 11, p. 622509, 2021, [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2020.622509/full

[33] S. Kaur *et al.*, "The looming storm: blood and cytokines in COVID-19," *Blood Rev.*, vol. 46, p. 100743, 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355567/

[34] M. Milenkovic *et al.*, "D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict in-hospital mortality in patients with COVID-19 pneumonia," *Oxid. Med. Cell. Longev.*, vol. 2022, no. 1, p. 8997709, 2022, [Online]. Available: https://www.hindawi.com/journals/omcl/2022/8997709/

[35] S. K. Byeon *et al.*, "Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study," *Lancet Digit. Heal.*, vol. 4, no. 9, pp. e632--e645, 2022, [Online]. Available: https://www.thelancet.com/journals/landig/article/PIIS2589-7500(22)00108-6/fulltext

[36] C. Botta *et al.*, "FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology," *Blood Adv.*, vol. 6, no. 2, pp. 690–703, 2022, [Online]. Available: https://ashpublications.org/bloodadvances/article/6/2/690/476395/FlowCT-for-the-analysis-of-large

[37] B. Vijayakumar *et al.*, "Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease," *Immunity*, vol. 55, no. 3, pp. 542–556, 2022, [Online]. Available: https://www.cell.com/immunity/fulltext/S1074-7613(22)00141-0

[38] L. Y. Tan, T. V Komarasamy, and V. R. M. T. Balasubramaniam, "Hyperinflammatory immune response and COVID-19: a double edged sword," *Front. Immunol.*, vol. 12, p. 742941, 2021, [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2021.742941/full

[39] D. M. Santer *et al.*, "Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity," *Nat. Commun.*, vol. 13, no. 1, p. 6992, 2022, [Online]. Available: https://www.nature.com/articles/s41467-022-34627-2

[40] M. Iannetta *et al.*, "Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study," *Sci. Rep.*, vol. 11, no. 1, p. 12762, 2021, [Online]. Available: https://www.nature.com/articles/s41598-021-92211-1

[41] M. Rudiansyah *et al.*, "Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism," *J. Med. Virol.*, vol. 94, no. 10, pp. 4611–4627, 2022, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/jmv.27829

[42] B. Soskic *et al.*, "Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation," *Nat. Genet.*, vol. 54, no. 6, pp. 817–826, 2022, [Online]. Available: https://www.nature.com/articles/s41588-022-01075-1

[43] Y. Que *et al.*, "Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality," *Int. Rev. Immunol.*, vol. 41, no. 2, pp. 217–230, 2022, [Online]. Available: https://www.tandfonline.com/doi/full/10.1080/08830185.2021.1916887

[44] T. P. Velavan *et al.*, "Host genetic factors determining COVID-19 susceptibility and severity," *EBioMedicine*, vol. 72, 2021, [Online]. Available: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00096-4/fulltext

***Husam Fadhil Hasan (Corresponding Author)**
Kut University College, Iraq
Email: Husam.Hamed@alkutcollege.edu.iq

Mojtaba Qati Dahdoh
Kut University College, Iraq
Email: Mojtaba.Hussin@alkutcollege.edu.iq

Hayder Mohsin Ali
Kut University College, Iraq
Email: Haider.Mahdi@alkutcollege.edu.iq